The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
SARS: Systematic Review of Treatment Effects
Open accessAbstract
BACKGROUND: The SARS outbreak of 2002-2003 presented clinicians with a new, life-threatening disease for which they had no experience in treating and no research on the effectiveness of treatment options. The World Health Organization (WHO) expert panel on SARS treatment requested a systematic review and comprehensive summary of treatments used for SARS-infected patients in order to guide future treatment and identify priorities for research. METHODS AND FINDINGS: In response to the WHO request we conducted a systematic review of the published literature on ribavirin, corticosteroids, lopinavir and ritonavir (LPV/r), type I interferon (IFN), intravenous immunoglobulin (IVIG), and SARS convalescent plasma from both in vitro studies and in SARS patients. We also searched for clinical trial evidence of treatment for acute respiratory distress syndrome. Sources of data were the literature databases MEDLINE, EMBASE, BIOSIS, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to February 2005. Data from publications were extracted and evidence within studies was classified using predefined criteria. In total, 54 SARS treatment studies, 15 in vitro studies, and three acute respiratory distress syndrome studies met our inclusion criteria. Within in vitro studies, ribavirin, lopinavir, and type I IFN showed inhibition of SARS-CoV in tissue culture. In SARS-infected patient reports on ribavirin, 26 studies were classified as inconclusive, and four showed possible harm. Seven studies of convalescent plasma or IVIG, three of IFN type I, and two of LPV/r were inconclusive. In 29 studies of steroid use, 25 were inconclusive and four were classified as causing possible harm. CONCLUSIONS: Despite an extensive literature reporting on SARS treatments, it was not possible to determine whether treatments benefited patients during the SARS outbreak. Some may have been harmful. Clinical trials should be designed to validate a standard protocol for dosage and timing, and to accrue data in real time during future outbreaks to monitor specific adverse effects and help inform treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There is no effective treatment to date, 17 and despite promising advances, 18,19 no vaccine has been approved.”
From Severe acute respiratory syndrome (SARS) mathematical models and disease parameters: a systematic review (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574 · cited 1×
“The causative organism has been identified as a novel coronavirus (SARS-CoV) [2] [3] [4] .”
BackgroundA Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344 · cited 2×
“The causative organism has been identified as a novel coronavirus (SARS-CoV) [2] [3] [4] .”
BackgroundMethodCoronavirus as a possible cause of severe acute respiratory syndrome
Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,915 · cited 1×
“The causative organism has been identified as a novel coronavirus (SARS-CoV) [2] [3] [4] .”
BackgroundA Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,628 · cited 1×
“Because the urgency of the international outbreak did not allow time for efficacy studies, physicians in Canada and Hong Kong treated the earliest patients with intravenous ribavirin, based on its broad-spectrum antiviral activity [9,10].”
BackgroundRole of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645 · cited 1×
“When LPV/r was added as an initial treatment to ribavirin and corticosteroid therapy, the death rate was lower than among those who received ribavirin and corticosteroids (1/ [20] .”
BackgroundClinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
Booth, C. M. (2003) · JAMA · doi:10.1001/jama.289.21.joc30885 · Cited by 1,406 · cited 2×
“Four publications presented evidence of possible harm (14) (15) (16) (17) .”
BackgroundResultThe Severe Acute Respiratory Syndrome
Peiris, J. S. M., Yuen, K. Y., Osterhaus, A. D. M. E., & Stöhr, K. (2003) · New England Journal of Medicine · doi:10.1056/nejmra032498 · Cited by 1,346
Identification of Severe Acute Respiratory Syndrome in Canada
Poutanen, S. M., Low, D. E., Henry, B., Finkelstein, S., Rose, D., Green, K., Tellier, R., Draker, R., Adachi, D., Ayers, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030634 · Cited by 1,132 · cited 1×
“Because the urgency of the international outbreak did not allow time for efficacy studies, physicians in Canada and Hong Kong treated the earliest patients with intravenous ribavirin, based on its broad-spectrum antiviral activity [9,10].”
BackgroundMeduri, G. U., Headley, A. S., Golden, E., Carson, S. J., Umberger, R. A., Kelso, T., & Tolley, E. A. (1998) · JAMA · doi:10.1001/jama.280.2.159 · Cited by 1,008 · cited 2×
“Table S11.”
BackgroundHigh-Dose Corticosteroids in Patients with the Adult Respiratory Distress Syndrome
Bernard, G. R., Luce, J. M., Sprung, C. L., Rinaldo, J. E., Tate, R. M., Sibbald, W. J., Kariman, K., Higgins, S., Bradley, R., Metz, C. A., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712173172504 · Cited by 935 · cited 1×
“In two trials, high-dose methylprednisolone given for approximately 2 d was not effective for early ARDS [ 25 ,26].”
Method
Research works printed but not linked: 30
- Ksiazek, 2003, N Engl J Med, 348, 1953
- Peiris, 2003, Lancet, 361, 1319
- Drosten, 2003, N Engl J Med, 348, 1967
- Peiris, 2003, N Engl J Med, 2003, 2431
- Leung, 2004, Ann Intern Med, 141, 662
- Fowler, 2003, JAMA, 290, 367
- Poutanen, 2003, N Engl J Med, 348, 1995
- Lee, 2003, N Engl J Med, 348, 1986
- Morgenstern, 2005, Biochem Biophys Res Commun, 326, 905
- Chen, 2004, J Clin Virol, 31, 69
- Knowles, 2003, Clin Infect Dis, 37, 1139
- Booth, 2003, JAMA, 289, 2801
- Sung, 2004, Thorax, 59, 414
- Wong, 2003, JAMA, 290, 2663
- Yamamoto, 2004, Biochem Biophys Res Commun, 318, 719
- Chan, 2003, Hong Kong Med J, 9, 399
- Chu, 2004, Thorax, 59, 252
- Lee, 2004, J Clin Virol, 31, 304
- Lee, 2004, Clin Infect Dis, 39, 1247
- Xiao, 2004, Zhonghua Nei Ke Za Zhi, 43, 179
- Li, 2004, Zhonghua Yi Xue Za Zhi, 84, 1348
- Bernard, 1987, N Engl J Med, 317, 1565
- Weigelt, 1985, Arch Surg, 120, 536
- Meduri, 1998, JAMA, 280, 159
- Scagnolari, 2004, Antivir Ther, 9, 1003
- Sainz, 2004, Virology, 329, 11
- Wu, 2003, Zhonghua Nei Ke Za Zhi, 42, 453
- Li, 2003, Zhonghua Er Ke Za Zhi, 41, 574
- Hwang, 2005, Mod Pathol, 18, 1
- Wang, 2003, N Engl J Med, 349, 507
Cited by
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
“Heart disease 586 (28) 1171 (27) 519 (34) 1074 (28) 164 (16)”
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
“79, 80 .”
Coronaviruses: An Overview of Their Replication and Pathogenesis
Fehr, A. R., & Perlman, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,787
“IFNs in combination with ribavirin may have increased activity in vitro when compared to IFNs alone against some coronaviruses; however, the effectiveness of this combination in vivo requires further evaluation [ 105 ].”
Background
Metadata
- Authors
- Stockman, L. J., Bellamy, R., & Garner, P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- James Cook University Hospital (GB)
- Liverpool School of Tropical Medicine (GB)
- Corresponding author
- Stockman, Lauren J
- ORCID
- Garner, Paul
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-09-12
- Volume
- 3
- Issue
- 9
- Pages
- e343
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC1564166
- OpenAlex
- W2054076340
- Semantic Scholar
- 1fabf8b5ddd4560d1ce7431b19642ab0e29847cc
- Cited by
- 1,217
- References
- 31
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 34 · 2023: 58 · 2022: 92 · 2021: 254 · 2020: 579 · 2019: 10 · 2018: 3 · 2017: 9 · 2016: 28 · 2015: 16 · 2014: 20 · 2013: 19 · 2012: 8
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (publishedVersion)
- LSTM Online Archive (Liverpool School of Tropical Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Department for International Development
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
- Keywords
- SARS, SARS-CoV, antiviral therapy, ribavirin, corticosteroids, type I interferon, intravenous immunoglobulin, convalescent plasma, acute respiratory distress syndrome, treatment efficacy, adverse effects, clinical trial design
- MeSH terms
- Disease Outbreaks, Humans, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS: Systematic Review of Treatment Effects. https://app.cochat.ai/papers/10.1371/journal.pmed.0030343
- The paper
- Stockman, L. J., Bellamy, R., & Garner, P. (2006). SARS: Systematic Review of Treatment Effects. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0030343
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
